55269-U
HybridSPE®-Phospholipid Ultra solid phase extraction (SPE) Cartridge
cartridge, bed wt. 30 mg, volume 1 mL, pk of 100
Synonym(s):
HybridSPE®-Phospholipid
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
UNSPSC Code:
41115712
NACRES:
NB.21
Recommended Products
product name
HybridSPE®-Phospholipid Ultra, cartridge, bed wt. 30 mg, volume 1 mL, pk of 100
material
PE frit (5-9 μm)
polypropylene hardware
Quality Level
composition
bed wt., 30 mg
packaging
pk of 100
technique(s)
solid phase extraction (SPE): suitable
volume
1 mL
matrix active group
zirconia-based phase
Looking for similar products? Visit Product Comparison Guide
General description
HybridSPE-Phospholipid technology is a simple and generic sample prep platform designed for the gross level removal of endogenous protein and phospholipid interferences from biological plasma and serum prior to LC-MS or LC-MS/MS analysis. Biological plasma or serum is first subjected to protein precipitation via the addition and mixing of acidified acetonitrile. Precipitated proteins are then removed by centrifugation and the resulting supernatant is loaded on the HybridSPE-Phospholipid 96-well plate or cartridge which acts as a chemical filter that specifically targets the removal of endogenous sample phospholipids. The phospholipid retention mechanism is based on a highly selective Lewis acid-base interaction between the proprietary zirconia ions functionally bonded to the HybridSPE-Phospholipid stationary phase and the phosphate moiety consistent with all phospholipids. The resulting eluent is ready for immediate LC-MS or LC-MS-MS analysis.
The "In-well" and "In-cartridge" precipitation methods are available for the HybridSPE-Phospholipid 96-well version and HybridSPE-Phospholipid Ultra cartridge in which biological plasma/serum is first added to either the well or cartridge, followed by acidified acetonitrile (precipitation agent). After a brief mixing/vortexing step, vacuum is applied. Because the 96-well and Ultra cartridge versions contain a series of low porosity hydrophobic filters/frits, the packed-bed filter/frit assembly acts as a depth filter facilitating the concurrent removal of both phospholipids and precipitated proteins during the extraction process. Standard HybridSPE-Phospholipid cartridges require an "off-line" precipitation method.
The "In-well" and "In-cartridge" precipitation methods are available for the HybridSPE-Phospholipid 96-well version and HybridSPE-Phospholipid Ultra cartridge in which biological plasma/serum is first added to either the well or cartridge, followed by acidified acetonitrile (precipitation agent). After a brief mixing/vortexing step, vacuum is applied. Because the 96-well and Ultra cartridge versions contain a series of low porosity hydrophobic filters/frits, the packed-bed filter/frit assembly acts as a depth filter facilitating the concurrent removal of both phospholipids and precipitated proteins during the extraction process. Standard HybridSPE-Phospholipid cartridges require an "off-line" precipitation method.
Features and Benefits
- Merges the simplicity of protein precipitation and the selectivity of SPE via the targeted removal of phospholipids
- Reduce ion-suppression through the complete removal of phospholipids and precipitated proteins
- 2-3 step generic procedure
- Minimal to no method development
- Available in 96-well and 1 mL cartridge dimensions
- Ultra cartridge allows the use of "In-cartridge" protein precipitation method
- Filtrate is ultra clean, free of fines, and suitable for direct injection in UHPLC-type applications
Legal Information
HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Development and validation of an HPLC-MS/MS method to determine clopidogrel in human plasma. Use of incurred samples to test back-conversion
Silvestro, L., et al.
Journal of Chromatography. B, Biomedical Applications, 878 (30), 3134-3142 (2010)
Solid-phase extraction of phosphorous-containing amino acid herbicides from biological specimens with a zirconia-coated silica cartridge
Watanabe, D., et al.
Journal of Chromatography. B, Biomedical Applications, 969, 69-76 (2014)
Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry
Deenen, M, et al.
Journal of Chromatography. B, Biomedical Applications, 913-914, 30-40 (2013)
C Ferreiro-Vera et al.
Journal of chromatography. A, 1240, 21-28 (2012-04-17)
Fractionation of biological fluids for proper analysis by LC-MS of low-abundance metabolites in the presence of high-abundant endogenous metabolites is of interest, particularly when the latter cause undesirable phenomena such as ionization suppression, as is the case with phospholipids (PLs).
Determination of carboplatin in human plasma using HybridSPE-precipitation along with liquid chromatography-tandam mass spectrometry
Hongliang, J,, et al.
Journal of Chromatography. B, Biomedical Applications, 879 (22), 2162-2170 (2011)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service